Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 12/20 | 0.31 |
| ▸ | ACHE | P22303 | 12/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446700 | 1.00 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL447626 | 1.00 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL3521680 | 0.90 | — | — | |
| SCHEMBL452206 | 0.87 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL448360 | 0.87 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL452117 | 0.87 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL449177 | 0.87 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL452380 | 0.84 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL450265 | 0.81 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL453032 | 0.77 | KDM4E (0.31) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065181-A1 | METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065181-A1 | METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS | SOD1, PYGB, PSAP | NPC1 955/4885RAB9A 3499/4885SMN1; SMN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.